WHY CANCER DRUGS COST
40-70% LESS IN CHINA
Advanced cancer drugs can cost USD 10,000-30,000 per month in the US. In China, the same drug class โ often domestically manufactured or biosimilar โ may cost USD 500-3,000. This guide explains why, what it means for patients, and how to evaluate whether treatment in China makes sense for your case.
analyticsAt a Glance
- check_circleChina is one of the world's largest producers of biosimilars, monoclonal antibodies, CAR-T products, and antibody-drug conjugates โ local manufacturing fundamentally reduces cost.
- check_circleDomestic competition between Chinese biotech companies creates pricing pressure that does not exist in markets dominated by a single originator product.
- check_circleGovernment pricing policy and national healthcare procurement negotiation further reduce costs for approved therapies in China.
- check_circleLower drug cost is real โ but total treatment cost includes diagnostics, hospital stay, travel, and follow-up. The full picture matters.
Why Advanced Cancer Drugs Cost Less in China
The cost difference between cancer treatment in China and in Western countries is frequently misunderstood. It is not about lower standards โ it is about fundamentally different cost structures across four areas.
Domestic Manufacturing Replaces Import Cost
When a drug is manufactured domestically, the production cost is calculated in local currency, using local labour, materials, and supply chains. The significant markups involved in importing, licensing, and distributing a product manufactured abroad are removed. For CAR-T therapy in particular, where the manufacturing process is the most expensive component, domestic production in China has reduced product costs by 60-80% compared with US prices.
Domestic Competition Between Multiple Developers
China has multiple domestic developers for many oncology therapy categories โ competing on price, trial access, and clinical performance. For targeted therapies, there may be five or more EGFR inhibitors available domestically, compared with one or two in Western markets. Competition between developers creates pricing pressure that reduces costs for patients across the market.
Government Pricing Negotiation
China's National Healthcare Security Administration negotiates drug prices through an annual national procurement process. Oncology drugs included in this process may see list prices reduced by 70-90% from their initial launch price in exchange for guaranteed volume. This policy has made several previously expensive targeted therapies widely accessible within China.
Clinical Trial Access at No Drug Cost
In active clinical trials, the experimental therapy is provided at no cost to the patient. China's large clinical trial ecosystem means many cutting-edge therapies โ including CAR-T products, bispecific antibodies, and ADCs โ are accessible through trial pathways where the drug itself is free, though total stay costs still apply.
Cost Comparison: Selected Therapy Categories
Indicative costs for key therapy categories. All figures approximate โ actual costs depend on specific product, centre, and patient situation.
CAR-T (CD19 โ DLBCL)
- China domestic productUSD 80,000-165,000
- USA (Kymriah / Yescarta)USD 350,000-465,000
EGFR Inhibitor (per month โ osimertinib equivalent)
- China (domestic / generic)USD 300-1,500
- USA (Tagrisso brand)USD 15,000-18,000
HER2 ADC (per cycle โ trastuzumab deruxtecan equivalent)
- China (domestic or via trial)USD 2,000-8,000
- USA (Enhertu brand)USD 20,000-30,000
The Full Cost Picture: Drug Cost vs Total Treatment Cost
Lower drug costs are real โ but the total cost of treatment in China includes more than the therapy product.
Costs That Are Lower in China
- The therapy drug or cell product itself40-80% lower for domestically manufactured products vs US or European branded equivalents.
- Hospital stay and room ratesDaily hospital costs significantly lower than US or European private hospitals.
- Diagnostic tests and laboratory workNGS, PET-CT, and other investigations typically 60-80% lower than in the US.
- Radiation therapy coursesFull IMRT/VMAT course USD 6,000-18,000 vs USD 40,000-90,000 in the US.
Costs That Still Apply
- International travel (flights)Return flights for patient and companion from South Asia: USD 1,000-2,000. From Middle East or Africa: USD 1,500-4,000.
- Accommodation for family members4-10 weeks accommodation near hospital: USD 2,000-8,000 depending on city and duration.
- Interpreter and coordination servicesProfessional medical interpreter for complex consultations and ongoing communication.
- Follow-up care at home after returningMonitoring, continuation drugs, and complication management upon return must be planned for.
Frequently Asked Questions
About Drug Costs in China
Does lower cost mean lower quality treatment in China?
No. The cost difference reflects manufacturing structure, competition, and pricing policy โ not clinical quality. China's major national cancer centres apply internationally recognised treatment protocols, use advanced equipment, and have specialist teams with significant clinical experience. Drug products manufactured in China meet NMPA regulatory standards. As with any country, quality varies between centres โ careful centre selection matters.
Which cancer treatments show the biggest cost difference in China?
The largest absolute cost differences are in CAR-T cell therapy (60-80% lower), targeted therapy for lung cancer (EGFR, ALK inhibitors โ up to 90% lower for domestic generics), antibody-drug conjugates, and proton or carbon ion therapy. Chemotherapy costs are also significantly lower. Radiation therapy (IMRT/VMAT) is typically 70-80% lower than in the US.
How does CancerFax help me understand the real total cost?
CancerFax requests centre-specific cost estimates as part of every case submission โ covering the therapy, hospital stay, diagnostics, and supportive care. We provide realistic cost ranges for travel and accommodation based on the treatment duration and destination. This gives patients a full picture before making any commitment to travel.
Is the cheaper treatment the same drug or a copy?
It depends on the therapy category. For targeted therapies like EGFR inhibitors, domestic Chinese generics and biosimilars contain the same active molecule and are approved by the NMPA. For CAR-T therapy, domestic products are developed by Chinese companies โ they target the same antigens (CD19, BCMA) but are distinct products with their own clinical data. They are not copies of US products, but independently developed therapies that achieve similar clinical goals.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand the Real Cost of Treatment in China for Your Case?
Share your medical reports โ our team will review your diagnosis and treatment goals and provide realistic cost estimates for relevant pathways in China, including the full picture beyond the drug cost alone.
Cost figures are indicative and subject to change. All treatment decisions must be made in consultation with a qualified oncologist.